Stay updated on Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial page.

Latest updates to the Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page no longer lists the condition Head and neck squamous cell carcinoma and removes related topics such as MedlinePlus Genetics.SummaryDifference0.1%

- Check12 days agoChange DetectedAdded related topic links: Head and neck squamous cell carcinoma and MedlinePlus Genetics; no changes to the study details or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedLocations section added with a comprehensive list of sites (Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas, Louisiana, Maryland, Michigan, Minnesota, New York, Oregon, Pennsylvania, South Carolina, Texas, Virginia, Ontario). The update replaces the previous per-location headings and removes the HHS Vulnerability Disclosure link.SummaryDifference2%

- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedRemoved the primary disease term 'Head and neck squamous cell carcinoma' and the related topic 'MedlinePlus Genetics' from the page, while updating the revision note from v3.3.1 to v3.3.2.SummaryDifference0.2%

- Check48 days agoChange DetectedAdded related topics including Head and neck squamous cell carcinoma and MedlinePlus Genetics, and updated the PubMed publication note by removing older phrasing.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page removed the government operating status notice and deleted the 'Head and neck squamous cell carcinoma' topic and the 'MedlinePlus Genetics' related topics section.SummaryDifference0.5%

Stay in the know with updates to Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab + Tremelimumab in Head and Neck Cancer Clinical Trial page.